NCT02600949View on ClinicalTrials.gov

Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

May 11, 2016

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions
Metastatic Colorectal AdenocarcinomaMetastatic Pancreatic Ductal AdenocarcinomaStage IV Colorectal Cancer AJCC v7Stage IV Pancreatic Cancer AJCC v6 and v7Stage IVA Colorectal Cancer AJCC v7Stage IVB Colorectal Cancer AJCC v7
Interventions
DRUG

Imiquimod

Applied topically

BIOLOGICAL

Pembrolizumab

Given IV

BIOLOGICAL

Sotigalimab

Given IV

BIOLOGICAL

Synthetic Tumor-Associated Peptide Vaccine Therapy

Given SC

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER